0001415889-24-015223.txt : 20240603
0001415889-24-015223.hdr.sgml : 20240603
20240603200009
ACCESSION NUMBER: 0001415889-24-015223
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240531
FILED AS OF DATE: 20240603
DATE AS OF CHANGE: 20240603
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brazzell Romulus K
CENTRAL INDEX KEY: 0001298079
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38150
FILM NUMBER: 241015691
MAIL ADDRESS:
STREET 1: C/O INSPIRE PHARMACEUTICALS, INC.
STREET 2: 4222 EMPEROR BLVD., SUITE 200
CITY: DURHAM
STATE: NC
ZIP: 27703
FORMER NAME:
FORMER CONFORMED NAME: Brazzell Kim
DATE OF NAME CHANGE: 20040722
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: KALA BIO, Inc.
CENTRAL INDEX KEY: 0001479419
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 270604595
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
BUSINESS PHONE: 781-996-5252
MAIL ADDRESS:
STREET 1: 1167 MASSACHUSETTS AVENUE
CITY: ARLINGTON
STATE: MA
ZIP: 02476
FORMER COMPANY:
FORMER CONFORMED NAME: Kala Pharmaceuticals, Inc.
DATE OF NAME CHANGE: 20091223
4
1
form4-06032024_080605.xml
X0508
4
2024-05-31
0001479419
KALA BIO, Inc.
KALA
0001298079
Brazzell Romulus K
C/O KALA BIO, INC.
1167 MASSACHUSETTS AVENUE
ARLINGTON
MA
02476
false
true
false
false
SEE REMARKS
0
Common Stock
2024-05-31
4
S
0
2002
6.09
D
89471
D
This sale was made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 9, 2020 to cover tax withholding obligations in connection with the vesting and settlement of the Reporting Person's restricted stock units ("RSUs") granted on May 31, 2023.
The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.07 to $6.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.
Includes 75,743 unvested RSUs.
Head of Research and Development and Chief Medical Officer
/s/ Mary Reumuth, Attorney-in-Fact
2024-06-03